

Remarks

Claims 1-6, 8, and 11-13 are pending in this application. Claims 1-6, 8 and 11 have been amended. Claims 12 and 13 have been added. Claims 7, 9 and 10 have been cancelled. No new matter has been added.

By way of this preliminary amendment, claims 1-6, 8 and 11 have been amended. These claim amendment are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments.

The subject matter of newly added claim 12 is disclosed in the application as filed in original claim 10. The subject matter of newly added claim 13 is disclosed in the application as filed in original claim 6.

In view of the above amendments and arguments, this application is deemed to be in a form suitable for US prosecution.

Respectfully submitted,



Dr. Tilman Breitenstein
Limited Recognition Under 37 CFR § 11.9(b)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175

Phone: (203) 812-2226
Date: 03/10/2005